United Kingdom · Question · Written question
UIN 139362
Non-tuberculous Mycobacteria: Amikacin
Introduced
14 March 2022
Last action
22 March 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
22 March 2022
Summary
To ask the Secretary of State for Health and Social Care, when NHS England’s Clinical Priorities Advisory Group will consider Arikayce liposomal as a treatment for patients with non-tuberculosis mycobacteria.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
14 March 2022
Written question
To ask the Secretary of State for Health and Social Care, when NHS England’s Clinical Priorities Advisory Group will consider Arikayce liposomal as a treatment for patients with non-tuberculosis mycobacteria.
Source: Commons
22 March 2022
Answer
A policy proposal for Arikayce Liposomal, also known as Amikacin, is being considered by NHS England and is progressing through its methods process. The policy proposal is currently undergoing stakeholder testing and a date for consideration at the Priori...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-03-14/139362
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1440730
- uk · wq-1440730 · source updated 22 March 2022